SMFM has released guidance on fetal growth restriction (FGR), an evidence-based document that provides a standardized approach to diagnosis and management. The document emphasizes the importance of FGR as a significant pregnancy complication that
…occurs in up to 10% of pregnancies and is second to premature birth as a cause of infant morbidity and mortality. In addition to its significant perinatal impact, FGR also has an impact on long-term health outcomes
ACOG FGR Definition
SMFM FGR Definition
Note: The term ‘IUGR’ should no longer be used | SMFM document, based on more recent evidence, does not consider symmetric vs asymmetric FGR to be helpful in determining prognosis
Early onset FGR: <32 weeks
Late onset of FGR ≥32 weeks
Severe FGR
NST (Cardiotocography [CTG])
Umbilical Artery (UA) Doppler Measurement
Note: SMFM recommends against routine use of ductus venosus dopplers, middle cerebral artery dopplers, or uterine artery doppler studies in early or late onset FGR | These studies have not been found to lead to improved accuracy over umbilical artery dopplers
Prevention
Treatment
Timing
Mode of Delivery
FGR and Preterm
SMFM Consult Series 52: Diagnosis and Management of Fetal Growth Restriction
ACOG Practice Bulletin 227: Fetal Growth Restriction
Are you an
ObG Insider?
Get specially curated clinical summaries delivered to your inbox every week for free
Please log in to ObGFirst to access this page
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
It appears you don't have enough CME Hours to take this Post-Test. We no longer offer Hours.
You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site